Optimal Dose and Timing of Umbilical Stem Cells Treatment in Pulmonary Arterial Hypertensive Rats

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2017 Mar 24

PMID 28332363

Citations 6

Authors

Hyeryon Lee

Kwan Chang Kim

Soo Jin Choi

Young Mi Hong

Affiliations

Soon will be listed here.

Abstract

Purpose: Pulmonary arterial hypertension (PAH) is a fatal disease which is characterized by an increase in pulmonary arterial pressure leading to increases in right ventricular afterload. Human umbilical cord blood derived-mesenchymal stem cells (hUCB-MSCs) administered via the jugular vein have been previously shown to improve PAH by reversal treatment. However, the effect of low dosage and transfusion timing of hUCB-MSCs on PAH has not yet been clearly established. Obviously, low dosage treatment can lead to a reduction in costs. This is the first study on early transfusion effect.

Materials And Methods: This study was divided into two parts. The first part is an investigation of dose-dependent effect. hUCB-MSCs were administered into 3 groups of rats (UA: 3×10⁶ cells, UB: 1.5×10⁶ cells, UC: 3×10⁵ cells) via the external jugular vein at week 1 after monocrotaline (MCT) injection. The second part is a search for optimal treatment timing in 3×10⁵ cells dose of hUCB-MSCs administered at day 1 for UD group (low dose of hUCB-MSCs at day 1), at day 1 and week 1 for the UE group (dual transfusion of low dose of hUCB-MSCs at day 1 and week 1) and at 1 week for the UF group (reversal treatment of low dose hUCB-MSC at week 1) after MCT injection.

Results: The administration of 3×10⁵ hUCB-MSCs was as effective as the 3×10⁶ dose in decreasing mean right ventricle (RV) pressure and pulmonary pathological changes. Early treatment with hUCB-MSCs improved mean RV pressure, pulmonary pathological changes and heart collagen 3 protein expression levels in PAH.

Conclusion: Low-dose early treatment of hUCB-MSCs is as effective as a high dose treatment of hUCB-MSCs in improving PAH although dual or reversal treatment is still more effective.

Citing Articles

Single high-dose intravenous injection of Wharton's jelly-derived mesenchymal stem cell exerts protective effects in a rat model of metabolic syndrome.

Chan A, Ng A, Mohd Yunus M, Idrus R, Law J, Yazid M Stem Cell Res Ther. 2024; 15(1):160.

PMID: 38835014 PMC: 11151561. DOI: 10.1186/s13287-024-03769-2.

Stem Cell and Exosome Therapy in Pulmonary Hypertension.

Oh S, Jung J, Ahn K, Jang A, Byun K, Yang P Korean Circ J. 2022; 52(2):110-122.

PMID: 35128849 PMC: 8819574. DOI: 10.4070/kcj.2021.0191.

Stem cells as a potential therapy in managing various disorders of metabolic syndrome: a systematic review.

Shamsuddin S, Chan A, Ng M, Yazid M, Law J, Idrus R Am J Transl Res. 2021; 13(11):12217-12227.

PMID: 34956448 PMC: 8661211.

Regenerative cell therapy for pulmonary arterial hypertension in animal models: a systematic review.

Suen C, Stewart D, Montroy J, Welsh C, Levac B, Wesch N Stem Cell Res Ther. 2019; 10(1):75.

PMID: 30841915 PMC: 6404277. DOI: 10.1186/s13287-019-1172-6.

Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies.

Ding X, Liang H, Yuan B, Li L, Wang T, Kan Q Stem Cell Res Ther. 2019; 10(1):55.

PMID: 30760312 PMC: 6374914. DOI: 10.1186/s13287-019-1162-8.

References

Jin Z, Pan X, Zhou K, Bi H, Wang L, Yu L . Biological effects and mechanisms of action of mesenchymal stem cell therapy in chronic obstructive pulmonary disease. J Int Med Res. 2015; 43(3):303-10. DOI: 10.1177/0300060514568733. View

Kern S, Eichler H, Stoeve J, Kluter H, Bieback K . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5):1294-301. DOI: 10.1634/stemcells.2005-0342. View

Ortiz L, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N . Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003; 100(14):8407-11. PMC: 166242. DOI: 10.1073/pnas.1432929100. View

Lee J, Fang X, Krasnodembskaya A, Howard J, Matthay M . Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011; 29(6):913-9. PMC: 3293251. DOI: 10.1002/stem.643. View

Souidi N, Stolk M, Seifert M . Ischemia-reperfusion injury: beneficial effects of mesenchymal stromal cells. Curr Opin Organ Transplant. 2012; 18(1):34-43. DOI: 10.1097/MOT.0b013e32835c2a05. View

Gnecchi M, Zhang Z, Ni A, Dzau V . Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103(11):1204-19. PMC: 2667788. DOI: 10.1161/CIRCRESAHA.108.176826. View

Zhao Y, Courtman D, Deng Y, Kugathasan L, Zhang Q, Stewart D . Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005; 96(4):442-50. DOI: 10.1161/01.RES.0000157672.70560.7b. View

Chang Y, Ahn S, Yoo H, Sung S, Choi S, Oh W . Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. 2014; 164(5):966-972.e6. DOI: 10.1016/j.jpeds.2013.12.011. View

Hansmann G, Fernandez-Gonzalez A, Aslam M, Vitali S, Martin T, Mitsialis S . Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ. 2012; 2(2):170-81. PMC: 3401871. DOI: 10.4103/2045-8932.97603. View

10.

Umar S, de Visser Y, Steendijk P, Schutte C, Laghmani E, Wagenaar G . Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009; 297(5):H1606-16. DOI: 10.1152/ajpheart.00590.2009. View

11.

Huertas A, Perros F, Tu L, Cohen-Kaminsky S, Montani D, Dorfmuller P . Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation. 2014; 129(12):1332-40. DOI: 10.1161/CIRCULATIONAHA.113.004555. View

12.

Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363(9419):1439-41. DOI: 10.1016/S0140-6736(04)16104-7. View

13.

Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008; 38(6):1745-55. PMC: 3021120. DOI: 10.1002/eji.200738129. View

14.

Zhang W, He L, Shi X, Wu S, Zhang B, Mei L . Regulation of transplanted mesenchymal stem cells by the lung progenitor niche in rats with chronic obstructive pulmonary disease. Respir Res. 2014; 15:33. PMC: 3987841. DOI: 10.1186/1465-9921-15-33. View

15.

Mei S, McCarter S, Deng Y, Parker C, Liles W, Stewart D . Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007; 4(9):e269. PMC: 1961632. DOI: 10.1371/journal.pmed.0040269. View

16.

Lee H, Lee J, Kwon J, Kim K, Cho M, Yang Y . The Effect of Umbilical Cord Blood Derived Mesenchymal Stem Cells in Monocrotaline-induced Pulmonary Artery Hypertension Rats. J Korean Med Sci. 2015; 30(5):576-85. PMC: 4414641. DOI: 10.3346/jkms.2015.30.5.576. View

17.

Rabinovitch M . Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012; 122(12):4306-13. PMC: 3533531. DOI: 10.1172/JCI60658. View

18.

Humbert M, Sitbon O, Simonneau G . Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351(14):1425-36. DOI: 10.1056/NEJMra040291. View

19.

Gitelman S, Haller M, Schatz D . Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 302(6):624. DOI: 10.1001/jama.2009.1098. View

20.

Lee H, Kim T, Choi K, Choi K . Effects of octylphenol on the expression of cell cycle-related genes and the growth of mesenchymal stem cells derived from human umbilical cord blood. Int J Mol Med. 2013; 33(1):221-6. DOI: 10.3892/ijmm.2013.1556. View